OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
October 22, 2021
Luminopia One is one of few digital therapeutics to receive FDA approval via the de novo pathway, and it is the first for amblyopia, and for a neuro-visual disorder in general.
October 21, 2021
In his presentation at ASRS 2021, Dr. Michael Singer divulges the results of the phase 2 study of formulations used to decrease macular edema in patients with retinal vein occlusion.
October 19, 2021
Leo Kim, MD, PhD, discusses his presentation at ASRS 2021, entitled "Rho-kinase inhibition on an in vitro patient-derived model of proliferative vitreoretinopathy."
October 18, 2021
Investigators find that long-term ocular complications require further observation.
October 16, 2021
The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.
October 14, 2021
On October 14, we celebrate World Sight Day by pledging to receive annual eye exams, preventing or slowing vision loss, and showing love for our eyes.
Today marks World Sight Day, an annual day of awareness intended to focus global attention on blindness and vision impairment. Coordinated by the International Agency for the Prevention of Blindness, this year’s call is for everyone to “Love Your Eyes.”
October 13, 2021
A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.
October 12, 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.